Stay updated on Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.

Latest updates to the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page
- Check4 days agoChange DetectedThe web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.SummaryDifference1.0%
- Check11 days agoChange DetectedThe website has been updated from version v2.14.1 to v2.14.2.SummaryDifference0.1%
- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedThe website has been updated from version 2.14.0 to 2.14.1.SummaryDifference0.1%
- Check32 days agoChange DetectedThe website has updated the 'type of intervention' feature from version v2.13.3 to v2.14.0, indicating a significant change in this aspect.SummaryDifference0.2%
- Check61 days agoChange DetectedThe website has been updated from version v2.13.2 to v2.13.3.SummaryDifference0.1%
- Check68 days agoChange DetectedThe website has updated the contact details section for the study, now providing information on who to contact for questions about joining the study and where it is taking place, reflecting a revision from v2.12.2 to v2.13.2.SummaryDifference2%
Stay in the know with updates to Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab for High-Grade Neuroendocrine Carcinomas Clinical Trial page.